

**NRG Oncology
SemiAnnual Meeting**

January 21 - 24, 2016 | Atlanta Marriott Marquis Atlanta, GA

2016 GYN Winter Symposium
“Immunotherapy for Cancer, Current Status and Future Prospects”

Thursday, January 21, 2016

8:00 am – 3 pm

Click [HERE](#) for Program Agenda

updated 10/22/15

PROGRAM DESCRIPTION:

The winter 2016 GOG Foundation, Inc. Educational Symposium is titled ***“Immunotherapy for Cancer, Current Status and Future Prospects,”*** with noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, and other MDs engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, and other interested Allied Health professionals. The speakers will focus their presentations on the mechanism by which cancer escapes the immune system. Presentations will also be focused on current and future strategies developing immunotherapies that address such mechanisms for good clinical outcomes.

LEARNING OBJECTIVES:

1. Recognize basic principles of immunology, both innate and adaptive, especially learn about the principles of T-cell biology and understand the function of different phenotypes of the cells.
2. Examine the interaction between the immune system and cancer cells and the effect of the tumor microenvironment on the immune system.

3. Identify tumor antigenicity and the different strategies that tumors develop to inhibit the immune system and escape an active immune response against tumor antigens.
4. Examine the current FDA approved immunotherapeutic approaches and agents that are currently in clinical trials, including vaccine, cytokines, and immune checkpoint inhibitors. Understand the basic principles behind the biology of these therapies and their clinical impact.
5. Distinguish novel immunotherapeutic agents that are under development, either in early clinical trial development or will be in clinical trials within the next 2-3 years. Analyze their mechanism of action and their potential in being used in specific conditions.
6. Analyze current and potential strategies in the development of combination immunotherapy, which is the way of the future in the therapy of cancer.
7. Recognize the uniqueness of clinical trial development in immunotherapy, including alternative clinical trial design and integration of specific immune biomarkers.
8. Recognize the specific regulatory consideration in immunotherapeutic developments and the interaction between regulatory agencies and developers and between different companies.